TOKYO, Apr 20 (Pulse News Wire) – DVx Inc. (3079.T) revised its fiscal year 2026 forecast, citing strong sales growth but lower-than-expected profits due to increased costs and changes in product mix.
For the fiscal year ending March 31, 2026, the company now expects revenue of ¥55.99 billion, up from the previous estimate of ¥51.96 billion. Operating profit is projected at ¥279 million, down from ¥581 million previously. Similarly, ordinary profit is expected to decrease to ¥299 million from ¥581 million, while net income per share is anticipated to drop to ¥189 million compared to ¥395 million earlier.
The revision reflects the rapid adoption of the company's atrial fibrillation treatment technology, "Pulse Field Ablation (PFA)," which led to unexpected shifts in demand within the arrhythmia sector. As a result, cost-of-sales ratios rose beyond initial projections, impacting profitability. Additionally, higher expenses related to inflation and investments in future growth further strained margins.
Despite the near-term challenges, DVx remains committed to enhancing profitability through strategic focus on high-margin products and services, alongside continuous operational improvements aimed at boosting gross margins and restoring earnings power.
Forecast revision — FY2026/3Mixed revision
| Metric | Prior | Revised | Change |
|---|---|---|---|
| Revenue | ¥51,956M | ¥55,989M | +7.8% |
| Op. profit | ¥581M | ¥279M | -51.9% |
| Net profit | ¥395M | ¥189M | -51.9% |
Source: TDNet filing · Figures in millions of yen
🟢 Confidence: High AI-translated content.